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The effect of propranolol on the prevention of ventricular tachycardia/fibrillation (VTNF) due to 
acute coronary ischaemia was studied in dogs. A series of propranolol-polymer controlled 
release matrices in slab configuration using various polyurethanes and a polyurethane-silicone 
rubber copolymer were formulated and characterized. In general, drug release in vitro occurred 
with an initial burst phase followed by an exponentially declining delivery rate; the silicone 
rubber containing copolymer preparation had more sustained release properties than did pure 
polyurethane matrices. In the animal studies, dogs underwent Shourly 10 min complete 
occlusions of the left anterior descending coronary artery (LAD), followed by 50 min normal 
perfusion. During non-drug occlusions VT occurred at a frequency of 1.22 -t 0.12 episodeslmin. 
A propranolol-polyurethane matrix (30% w/w, 26-42 mg) was placed on the ischaemic zone of 
the left ventricular epicardium immediately after the fifth occlusion. After an hour of drug 
delivery a sixth occlusion took place. The number of arrhythmia episodes both before and after 
drug were quantified and compared. The time to ventricular fibrillation (when present) and the 
mean blood pressure were also assessed. The drug patch delivered propranolol at a dose of 
140 + 45 pglkg by the conclusion of the 1 h study period. Therapeutic drug levels were achieved 
in the peripheral blood samples (8.7-43.7 ng/ml) and were enhanced in coronary venous 
samples (360.9-556.2 ng/ml). Reduction of blood pressure and proarrhythmic events following 
epicardial controlled release propranolol administration were noted but were not statistically 
significant. Arrhythmia episodes before and after propranolol were not found to be significantly 
different (VT/min 1.02 k 0.31 and 1.22 +_ 0.12). The occlusion time until VF occurred was also 
not significantly different before versus after propranolol (t = 5.38 f 0.86 and 5.28 + 0.48 min). 
Therefore, despite attaining clinically therapeutic plasma levels, epicardial administration of 
propranolol was not found to be effective for the prevention of VTNF due to acute ischaemia. 
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Ventricular arrhythmias are the most frequent cause of 
morbidity and mortality among patients with coronary 
heart diseaselm3. Sustained ventricular tachycardia [VT) 
and ventricular fibrillation (VF) occurring after 
myocardial infarction are common and life threatening’. 
A variety of antiarrhythmic drugs are available for the 
management of ventricular arrhythmias’* 3-5, However, 
all of these agents have limitations. Undesirable 
characteristics such as narrow therapeutic indices” 4, 
cardiac and extracardiac side-effects3-5, and 
proarrhythmic potential’, limit the doses that can be 
administered systemically, thus complicating the treat- 
ment. When combination therapy is used, there is a 
potential for hazardous drug interactions’. 
Correspondence to Dr Robert J. Levy, University of Michigan, 
Department of Pediatrics, R5014 Kresge II 0576, Ann Arbor, MI 
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Since both the current pharmacological and the non- 
pharmacological treatments for ventricular arrhythmias 
are often ineffective and even dangerous, there is still 
need for an improved long-term therapeutic approach. A 
novel approach is the administration of the anti- 
arrhythmic drugs directly to the myocardium by 
implantable controlled release drug delivery 
systems’-ll. 
Prior work has demonstrated that local controlled 
release administration of antiarrhythmic drugs using 
several different dog models was effective. For example, 
formulating a lidocaine-polyurethane controlled release 
matrix and implanting this drug delivery system on to the 
epicardium was found to be effective in converting 
ouabain-induced ventricular tachycardia in dogs to sinus 
rhythm’. Both lidocaine and procainamide polyurethane 
matrices were found effective for converting ventricular 
tachycardia induced by rapid ventricular pacing to sinus 
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rhythm. Allowing those matrices to remain on the heart 
muscle for 4 h resulted in a ventricular tachycardia 
electrical induction threshold elevation that demonstrated 
a prolonged effect of those antiarrhythmic drugs97 lo. A 
verapamil-polyurethane matrix system was also found 
to be effective for reducing the number of VTIVF 
episodes due to a complete occlusion of the left anterior 
descending coronary artery (LAD) in dogs”. 
The doses of the antiarrhythmic drugs in all the above 
studies were significantly lower than conventional 
systemic doses. Coronary blood levels were found to be 
in the therapeutic range while peripheral blood levels, 
when detectable, were far below the therapeutic or the 
toxic range’-“. These results demonstrate the ability to 
treat ventricular arrhythmias by transmyocardial drug 
a’dministration in experimental models. This route of 
administration has also been shown to optimize efficacy 
by enhancing local therapeutic concentrations, while 
minimizing general toxicity due to elevated plasma 
levels. 
Controlled release matrices for the delivery of drugs 
locally to the heart were found to be effective in several 
other disease processes. For example, local delivery of 
gentamicin has made possible the prevention of bacterial 
endocarditis in a dog model”. Other studies have 
demonstrated the efficacy of both site-specific controlled 
release dexamethasone for the inhibition of fibrous 
tissue build-up near a pacing catheter13, and 
diphosphonate matrix placement next to bioprosthetic 
heart valve leaflet implants for the prevention of 
calcification’4. 
Controlled release of P-adrenergic antagonists has not 
been investigated for antiarrhythmia therapy. P-Adrenergic 
blockers have been classified as Type II antiarrhythmic 
drugs15. Currentlyp-adrenergic blockers are not first-line 
clinical agents for the treatment of any specific ventricular 
arrhythmia except in cases where the arrhythmia is 
associated with elevated catecholamine levels4, 5. 
However, the use of P-adrenergic blockers is well 
established in the treatment of atria1 arrhythmias41 5, 16. 
Furthermore, a number of clinical studies have demon- 
strated that administration of P-blockers prophylacti9ally 
to patients after myocardial infarction can reduce 
cardiac mortality’, 4, ‘. 17, presumably due to preventing 
ventricular arrhythmias during subsequent ischaemic 
episodes. Other clinical studies have indicated that the/I- 
adrenergic blockers can be useful in the treatme+ of 
benign or potentially fatal ventricular arrhythmias”, 
treating patients with sustained ventricular 
tachyarrhythmiaslg, and preventing sudden deathzO-“. 
A study that examined the effects of either timolol or 
propranolol on inducible sustained tachyarrhythmias in 
dogs found that both these P-blockers drugs were 
effective in abolishing inducible VT or VF in the dog with 
myocardial infarctionz3. Work by others using acute 
ischaemia models in dogs24-26 has also demonstrated that 
systemic administration of propranolol reduced the 
incidence of ventricular arrhythmias. Thus, both the 
clinical and the animal studies of the /I-adrenergic 
blockers have established their potential usefulness in 
treating ventricular arrhythmias. 
In the present study propranolol, a non-specific 
moderately potent /?-blocker, served as a model drug for 
studying the effect of P-blockers on the ischaemic 
heart, when administered locally, directly to the 
myocardium via a controlled release matrix. The objectives 
of this study were: 
To formulate and characterize the in vitro release 
profile of propranolol from various polymeric matrix 
preparations and to choose a suitable matrix for in 
vivo studies. 
To study the pharmacological effects of the 
propranolol matrix in vivo for inhibition of ventricular 
arrhythmias in an ischaemic model in dogs. 
To examine and compare coronary and peripheral 
propranolol blood levels during controlled release 
epicardial drug delivery. 
EXPERIMENTAL 
Materials 
Propranolol hydrochloride and quinidine (HPLC internal 
standard] were obtained from Aldrich Chemical Corp. 
[Milwaukee, WI, USA). Two proprietary polyether 
(polytetramethylene glycol) polyurethanes MPU-5 
(Matrix Media Inc., Wheat Ridge, CO, USA) and Biomer 
(Ethicon, Somerville, NJ, USA] were used, as 25% and 
30% in dimethylacetamide. A proprietary polyurethane- 
silicone rubber copolymer 6605-41 (Dow Corning Corp., 
Midland, MI, USA) was also used for preparing drug 
matrices. HPLC grade acetonitrile and methanol were 
obtained from Mallinckrodt Inc. (Paris, KY, USA]. HPLC 
grade ether and phosphoric acid (65%) were obtained 
from Fisher Scientific [Pittsburgh, PA, USA). 
Dimethyacetamide (DMA) and ascorbic acid were 
purchased from Sigma (St Louis, MO, USA). 
Apparatus 
Electrocardiograms were continuously recorded on a 
Hewlett-Packard 3698A Instrumentation Recorder 
(Andover, MA, USA], displayed on AST premium 286 
computer (AST Research Inc., Irvin, CA, USA), using a 
Codas analog to digital conversion board plus software 
(Data Q Instruments Inc., Akron, OH, USA]. Periodically 
physiological readings were also produced using a 
pressurized ink system (Hewlett-Packard, Model PDR- 
HP). A programmable stimulator (Grass Instruments, 
Model S68, Quincy, MA, USA] coupled to an optically 
isolated constant current source [Bloom Associated Ltd, 
Reading, PA, USA) were used for pacing. Propranolol 
assays were carried out with a high-performance liquid 
chromatograph [Waters 501 HPLC Pump, Waters Inc. 
Milford, MA, USA] with a Waters 689 Automatic 
Gradient Controller which was equipped with a prepacked 
Cl8 precolumn (Waters Inc.) and an Altex Ultraspheric- 
ODS, 25 cm X 4.6 mm column (Beckman Inc., San 
Ramon, CA, USA). The detection of the drug was carried 
out with a Waters 470 scanning fluorescent detector and 
chromatograms were received on a Waters 740 Data 
Module (Waters Inc.). 
METHODS 
Matrix formulation and in vitro release studies 
Propranolol hydrochloride matrices were prepared by 
dissolving the drug in DMA and adding the polymer of 
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interest already dissolved in DMA. The mixture was then 
poured into Teflon@’ coated Petri dishes (10 cm diameter) 
and were dried in a vacuum oven at SO’C for 48 h. 
Propranolol polymer films were cut into 1 X 1 cm 
(200pm thick) squares for in vitro release, in triplicate, 
using 0.05 ITIM phosphate buffer under perfect sink 
conditions (20 ml volumes at pH 7.4, 37’C, 45 rev min-’ 
changed daily). Propranolol release was quantitated by 
UV absorbance (&,, = 289 nm). The calibration curve 
was found to be linear in the range that was used (5- 
100 fl l/ml). 
Stability test 
To assess the stability of propranolol during the in vitro 
release study and storage periods, six solutions in a 
concentration range S-100 ng/ml were prepared, divided 
into groups and stored at 4 and 37’C. The UV readings of 
the freshly prepared solutions were compared with the 
UV readings of the same solutions after 1 and 7 d in the 
storage conditions. 
Dog model of iscbaemic ventricular tacbycardia 
(VT) and ventricular fibrillation (VP) 
Six male mongrel dogs (24-35 kg) underwent a left 
thoracotomy and pericardiotomy under pentobarbital 
anaesthesia. A bipolar platinum electrode was placed on 
the left atria1 appendage and pacing was carried out 
during each study at 180 beatslmin using twice the 
diastolic capture threshold current. Surface electrodes 
and unipolar epicardial electrodes (on ischaemic and 
non-ischaemic zones of the left ventricle) were used for 
electrocardiogram recordings. The blood pressure and 
the pacing electrode signal were also recorded. Each 
animal was subjected to &hourly 10 min complete 
occlusions of the LAD followed by 50 min of normal 
perfusion. Five replicate occlusions were carried out to 
assure the reproducibility of arrhythmias in each dog 
before therapy. This dog model is a modification of the 
method described by Elharrar et aLz7. In the current 
model, the hearts underwent a 10 min complete occlusion, 
as opposed to 8 min used by Elharrar et al.27. To 
normalize the data, the numbers of premature beats (PM), 
doublets (DB) and ventricular tachycardia (VT) episodes 
were calculated per minute. One of the common con- 
sequences of the repeated occlusions was ventricular 
fibrillation (VF) either during the occlusion or with 
reflow. In the event of fibrillation during an occlusion, 
the occluder was released and the dog resuscitated with a 
DC defibrillator. 
Arrhythmia episodes were counted during each 
occlusion period and during the intervening periods after 
the fourth and fifth occlusions. Two consecutive pre- 
mature beats were defined as a doublet while three or 
more were defined as ventricular tachycardia. 
Immediately after the fifth occlusion a propranolol patch 
was put on the LAD ischaemic zone. After the patch was 
in place for an hour the last 10 min occlusion was carried 
out. Blood samples were collected from the femoral and 
regional coronary veins every 10 min during the drug 
study period. Before storage at -20°C ascorbic acid (to a 
5 mg/ml concentration) was added to the separated 
plasma to prevent propranolol oxidation”. 
Blood samples analysis 
Peripheral and coronary venous propranolol levels were 
measured using a modification of an HPLC method that 
was described by Abdel-Hamid’*. To a 1 ml aliquot of 
thawed peripheral plasma samples 100~1 of internal 
standard solution (Quinidine, 10 pg/ml), 1 ml of a sodium 
hydroxide soIution (1.0 M), 1 ml of water and 5 ml ether 
were added. After vortexing for 30 s and centrifuging for 
10 min at 1800 rev min-’ the aqueous layer was frozen 
over an isopropranol-dry ice bath and the ethereal phase 
was separated. Then 200~1 0.1% phosphoric acid 
containing 5 mg/ml ascorbic acid were added to the 
ethereal phase, mixed, centrifuged and frozen. After 
discarding the ethereal layer the frozen pellets were 
thawed and 50 ~1 were injected into the HPLC. From the 
thawed coronary plasma only 0.5 ml aliquots were taken 
and NaOH (0.25 ml) and water (0.25 ml) were added. A 
calibration curve was prepared in 1 ml blank dog plasma 
containing 5 mg/ml ascorbic acid and was found to be 
linear in the range that was checked (lo-300 @/ml). 
Residual matrix drug detection 
Retrieved propranolol hydrochloride matrices in MPU-5 
were extracted with methanol in a Soxhlet apparatus 
(Fisher Scientific). The extracts were analysed by HPLC 
(see later) and the net in viva release was calculated. 
HPLC conditions 
An isocratic separation was achieved as follows: the 
mobile phase was prepared by combining 56 ml phos- 
phoric acid solution (0.02 M, pH 4) with 28ml of 
acetonitrile and 18 ml of methanol’*. The flow rate was 
1 ml/min. A combination of 212 nm excitation filter and 
340 nm emission filter were used for fluorescence 
detection. These conditions were used for quantitation of 
both the residual matrix propranolol after application 
and the blood samples. 
RESULTS 
In vitro release 
Propranolol was previously foundz9 to be unstable at 
alkaline pH. To be certain that propranolol was stable 
during the release study at 37’C and during storage at 
4°C the slopes of the calibration curves were compared 
after storage at each temperature. The slope of the 
‘freshly prepared’ calibration curve was not found to be 
significantly different from the slopes of the calibration 
curves of the solutions stored at 37 and 4°C after 1 d 
(y = 1.88 X 10~‘x, 1.87 X lO%, 1.86 X lo-‘x) or 7 d 
(y = 1.86 X lo-‘x, 2.03 X lo-%, 1.89 X lo-‘x). 
The release rates of propranolol from four different 
formulations were quantified and compared up to 10 d 
[Figure 2). While the polyurethane preparations were 
releasing most of the drug during the first day, the 
copolymer matrix released only about 15% of its content 
over 10 d. When comparing the release up to 60 min, 
which was the duration of the in viva release up to the 
drug test occlusion it was found that the matrix that 
contained 30% propranolol hydrochloride in MPU-5 
released 88.5 f 4.4% (mean+SD). However, the 20% 
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Figure 1 Propranolol in vitro release as cumulative percentage 
(37”C, pH 7.4) from 30% MPU-5 (D), 20% MPU-5 (0). 20% 
polyurethane-silicone rubber copolymer (B) and 20% Biomer 
(0). a, 24 h, b, 10 d. 
propranolol loaded matrices in MPU-5, Biomer and the 
copolymer released 47.2 t 3.99b, 48.7 i 5.5% and 
3.25 k 0.3% respectively. Since the amount of drug 
released from the 30% MPU-5 matrices was significantly 
greater than the amount released from the 20% prepara- 
tions in MPU-5 and Biomer ft = 8.36, P = 0.001 and 
t = 6.81, P = 0.002 respectively) the matrix that contained 




Following in vivo release (70 min) in the dogs, the drug 
matrices were extracted for residual propranolol content. 
It was found that 140 + 45 ,ug/kg of propranolol were 
delivered. 
Ucclusion experjmen fs 
Analyses of the frequency of the different types of 
ventricular arrhythmias, premature (PM), doublet (DB) 
and ventricular tachycardia (VT) beats during the 
occlusion periods and during the intervals following the 
fourth and fifth occlusions demonstrated that frequencies 
of each type of ventricular arrhythmia per minute during 
acute ischaemia were not significantly different with or 
without propranolol. VT frequencies (episodes per minute, 
mean + standard error) for occlusions 1 through 5 were 
1.40 + 0.38, 1.09 + 0.35, 0.80 + 0.32, 1.18 + 0.60 and 
1.34 + 0.49 respectively. Following 1 h propranolol 
epicardial administration VT frequency was 1.02 + 0.31. 
The results are summarized in Table 3 and Figure 2. To 
examine the p~~h~hrnic effect of propranolol, the 
interval following the fourth occlusion, before the drug 
matrix was sewn on, and the interval after the fifth 
occlusion, following the matrix placement, were com- 
pared. Although the frequency of PM beats, DB and VT 
per min was greater during the hour after propranolol 
was administered to the heart compared to the control the 
differences were not significant statistically (P > 0.5, 
Student’s t test). Propranolol also tended to reduce the 
mean blood pressure: the reduction was also not 
significant statistically (P > 0.5) compared to control. In 
addition, propranolol did not influence the onset of 
ventricular fibrillation. 
Peripheral versus coronary blood levels following 
epicardial propranolol 
Peripheral propranolol levels ranged from 8.7 to 
43.7 nglml, while simultaneous coronary blood levels 
were significantly elevated (P < 0.001) compared with 
peripheral levels, and ranged from 360.6 to 556.2 rig/ml 
(Figure 3), emphasizing the enhanced regional nature of 
epicardial controlled release therapy. 
DISCUSSION 
In the present study the in vitro release rate was found to 
be influenced by the nature of the polymer in which the 
drug was compounded. The release rate from MPU-5, the 
most hydrophilic polymer used in our investigation, was 
significantly higher than the release rate from the other 
polyurethane studied, Biomer< which is relatively less 
hydrophilic than MPU-5. Furthermore the release rate of 
propranolol from the copolymer 6605-41 which was the 
least hydrophilic polymer investigated, since it is a 
polyurethane-silicone rubber, was more sustained than 
noted with MPU-5 or Biomer. The same trend was 
previously found3* for the release of FeCl, and Al(NO,), 
from Biomer and the copolymer 6605-41. The ability of 
these various polymer matrices to deliver a range of 
antiarrhythmic drug doses over prolonged periods of 
time is of particular importance; for an acute arrhythmia 
a higher dose for a short period of time might be needed, 
while for maintenance of an inhibitory drug level for 
chronic arrhythmia therapy a lower dose over a long 
period of time might be needed. 
The propranolol coronary blood levels were also 
shown to be up to 50 times greater than the peripheral 
levels. This result emphasizes the propensity for epicardial 
controlled release to achieve regionally high drug levels 
while minimizing the magnitude of systemic blood 
levels. The same phenomenon was demonstrated when 
either lidocaineg or procainamide” were administered to 
the heart by controlled release matrices. Plasma pro- 
pranolol levels of up to 1000 nglml may be required to 
control resistant ventricular arrhythmias based on 
clinical results*. However, only 25% of the usual 
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Table 1 Comparison of frequencies of arrhythmic episodes, time to VF and blood pressure with and without propranolol* 
Control 
(1st to 5th 
occlusions combined) 
Propranolol 4th reflow 5th reflow 
Occlusions (n) 30 6 6 
PM/min 2.5 + 0.68’ 2.84 + 0.69 
:.I0 
zk 0.06 0.46 L 0.27 
DB/min 0.75 + 0.31 0.69 + 0.14 0.03 + 0.03 0.28 f 0.14 
VTlmin 1.22 + 0.12 1.02 + 0.31 0.02 f 0.01 0.07 Ik 0.05 
Time to VF (min) 5.28 f 0.48 5.38 f 0.88 
Mean BP (mmlig) 153.6 f 6.5 131.3 + 16.5 
Data are mean + sem. 
PM, premature; DE. doublet; VT, ventricular tachycardia; VF, ventricular fibrillation: BP, blood pressure. 
antiarrhythmic dose, 140 ,~~g/kg, was needed to achieve a 
nearly maximal therapeutic level in the coronary blood in 
the present study. Also, according to our results, when 
propranolol was given locally the peripheral drug levels 
were within the low end of the therapeutic range for 
L 
l- 
Control Propanolol 4th reflow 5th reflow 
Frequency of arrhythmia episodes with and without Figure 2 
propranorol during occlusion and reflow. Isolated premature 
beats (Ii), doublets (El), ventricular tachycardia (W). 
0 20 40 60 80 
Time (min) 
Figure 3 Propranolol plasma levels (ng/ml, means + standard 
errors). Coronary (0) peripheral (0). 
treating angina and hypertension based on clinical 
studies4. 
Although propranolol epicardial administration resulted 
in significantly higher blood levels in the heart compared 
with the peripheral blood, no significant antiarrhythmic 
effect was demonstrated. Furthermore, peripheral plasma- 
propranolol levels were also in the therapeutic range 
relative to clinical data concerning both arrhythmia 
therapy and hypertensions20-22~ 31. Prior animal and 
clinical studies have also demonstrated that systemic 
propranolol reduces the occurrence of ventricular 
arrhythmias due to myocardial ischaemia20-22~ 24-26 or 
infarctionl* 43 ‘, I78 “. Furthermore, systemic administration 
of propranolol by others has been effective in dog models 
of ischaemia comparable to ours24-26 and also infarction- 
related arrhythmias using net total dosages comparable 
to those used in the present study”. These prior studies 
cannot be viewed as providing systemic drug administra- 
tion of relevance for the present experiments. Thus, 
additional drug protocols in the present series of studies 
could have compared an array of systemic dosages of 
propranolol to the epicardial results. However, the lack 
of any antiarrhythmia activity with epicardial controlled 
release compared to non-drug coronary occlusions, 
despite near maximal coronary venous drug concentrations, 
and systemic hypotension obviates the usefulness of 
further studies along these lines. Furthermore, a relevant 
systemic dose for comparisons with the epicardial 
studies might have involved giving the same dose 
administered by the matrix intravenously over 1 h, or 
administering an appropriate intravenous dose based on 
pharmacokinetic parameters to achieve a systemic or 
coronary propranolol level identical to that achieved 
with epicardial administration. Other treatment groups 
could also have considered regional intracoronary 
injection of propranolol or coronary venous retro- 
perfusion, again to obtain coronary venous plasma levels 
identical to those achieved with a matrix. These other 
administration variations were beyond the scope of this 
study but may be worth further consideration. 
In addition the present results suggest that while 
systemic P-blockade may be effective for ventricular 
arrhythmias this is likely be due to central effects rather 
than directly influencing cardiac /I-adrenergic activity. 
Alternatively, D-propranolol for suppression of ventricular 
arrhythmias in man has recently been shown to be as 
effective as the racemic preparation3’, thereby demon- 
strating that propranolol’s efficacy for ventricular 
arrhythmias may not be entirely related to its p -blocking. 
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Table 2 Comparisons of epicardial polymeric (polyurethane) controlled release therapy: results of acute ischaemia-ventricular 






No therapy - 
Mechanisms 
Na channel blockade 
P-blocker 
Delayed repolarization 



















0.6 + 0.2 
1.22 + 0.12 
0.46 + 0.11 
0.10 f 0.03 
1.10 + 0.30 
aModified from Levy et al., in Cosmetic and Pharmaceutical Application of Polymers, Plenum, NY, USA, 1991, pp 231-238 
bVaughan Williams classification’5. 
Therefore, propranolol’s failure to affect ventricular 
arrhythmias via epicardial administration may be due to 
complex and incompletely understood factors. 
The tendency observed in the present studies for 
epicardial propranolol to reduce blood pressure and to 
intensify arrhythmias during non-ischaemic periods was 
not found to be statistically significant. Nevertheless, 
this possible P-adrenergic antagonist effect might be 
better investigated in further experiments planned with 
sotalol. Sotalol, a relatively new antiarrhythmic drug, 
ha8 two active stereoisomers. The L-isomer hasp-blocker 
activity, while D-8OtalOl is classified as a class 111 
antiarrhythmic drug33. Thus, experiment8 with each of 
the isomers and with the racemic mixture might be most 
useful for further studying the importance of P-blockers 
for antiarrhythmia therapy. 
Despite the lack of effectiveness of epicardial 
controlled release propranolol in this ischaemic ventri- 
cular arrhythmia model system, virtually all the other 
classes of antiarrhythmic agents have been shown to be 
effective for decreasing the occurrence ischaemic 
arrhythmias in this dog model when administered by 
epicardial controlled release matrices (Table 2134. Thus, 
further research investigating myocardialp-blockade via 
epicardial controlled release may not prove to be as 
fruitful as other mechanistic strategies. 
CONCLUSIONS 
Propranolol, serving as a modelp-adrenergic antagonist, 
was successfully delivered from a polyurethane matrix 
placed on the left ventricular epicardium in dogs. 
Although potentially therapeutic blood levels were 
achieved both in the heart and in the periphery, 
epicardial propranolol, while causing mild hypotension, 
failed to prevent ventricular arrhythmias due to acute 
ischaemia. Thus it was not found to be useful as a 
treatment for ventricular arrhythmia8 due to acute 
ischaemia in a dog model system. 
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